Treg-specific IL-2 therapy can reestablish intrahepatic immune regulation in autoimmune hepatitis

Treg-mediated prolonged survival of skin allografts without immunosuppression

(2019) Nina Pilat et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Applicability, Safety And Biological Activity Of Regulatory T Cell Therapy In Liver Transplantation

(2019) Alberto Sánchez‐Fueyo et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Low-Dose IL-2 Therapy in Transplantation, Autoimmunity, and Inflammatory Diseases

(2019) Maryam Tahvildari et al.   JOURNAL OF IMMUNOLOGY

Autoimmune hepatitis induction can occur in the liver

(2019) Janine Dywicki et al.   LIVER INTERNATIONAL

Low Dose Interleukin-2 for Refractory Autoimmune Hepatitis

(2018) Tiong Y. Lim et al.   HEPATOLOGY

Pharmacodynamics of regulatory T cells in mice and humans treated with low-dose IL-2

(2018) Guillaume Churlaud et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

A human anti-IL-2 antibody that potentiates regulatory T cells by a structure-based mechanism

(2018) Eleonora Trotta et al.   NATURE MEDICINE

Immunological and clinical effects of low-dose interleukin-2 across 11 autoimmune diseases in a single, open clinical trial

(2018) Michelle Rosenzwajg et al.   ANNALS OF THE RHEUMATIC DISEASES

The influence of genetic predisposition and autoimmune hepatitis inducing antigens in disease development

(2017) Matthias Hardtke-Wolenski et al.   JOURNAL OF AUTOIMMUNITY

Regulatory T-cell therapy in liver transplantation

(2017) Gavin P. Whitehouse et al.   TRANSPLANT INTERNATIONAL

Cutting edge issues in autoimmune hepatitis

(2016) Rodrigo Liberal et al.   JOURNAL OF AUTOIMMUNITY

Low-dose interleukin-2 treatment selectively modulates CD4+ T cell subsets in patients with systemic lupus erythematosus

(2016) Jing He et al.   NATURE MEDICINE

Regulatory T Cell Responses in Participants with Type 1 Diabetes after a Single Dose of Interleukin-2: A Non-Randomised, Open Label, Adaptive Dose-Finding Trial

(2016) John A. Todd et al.   PLOS MEDICINE

Low-dose interleukin-2 selectively corrects regulatory T cell defects in patients with systemic lupus erythematosus

(2015) Caroline von Spee-Mayer et al.   ANNALS OF THE RHEUMATIC DISEASES

Low-dose interleukin-2 fosters a dose-dependent regulatory T cell tuned milieu in T1D patients

(2015) Michelle Rosenzwajg et al.   JOURNAL OF AUTOIMMUNITY

EASL Clinical Practice Guidelines: Autoimmune hepatitis

(2015)   JOURNAL OF HEPATOLOGY

Type 1 diabetes immunotherapy using polyclonal regulatory T cells

(2015) Jeffrey A. Bluestone et al.   Science Translational Medicine

Intrahepatic regulatory T cells in autoimmune hepatitis are associated with treatment response and depleted with current therapies

(2014) Richard Taubert et al.   JOURNAL OF HEPATOLOGY

Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

(2014) Erika Assarsson et al.   PLoS One

Genetic predisposition and environmental danger signals initiate chronic autoimmune hepatitis driven by CD4+T cells

(2013) Matthias Hardtke-Wolenski et al.   HEPATOLOGY

Low-dose interleukin 2 in patients with type 1 diabetes: a phase 1/2 randomised, double-blind, placebo-controlled trial

(2013) Agnès Hartemann et al.   Lancet Diabetes & Endocrinology

Diagnosis and management of autoimmune hepatitis

(2010) Michael P. Manns et al.   HEPATOLOGY